How a US Healthcare Provider Complied with DSL for Clinical Data in China: A Case Study
In Q1 2025, a US-based healthcare provider successfully completed a cross-border clinical data transfer compliant with China’s Data Security Law (数据安全法, DSL, shùjù ānquán fǎ) after a 14-month remediation project involving 120,000 patient records, avoiding penalties of up to 50 million yuan. This case study examines how MedBridge Health (a pseudonym for a real US hospital network) achieved compliance for its China-based clinical trial data shared with its US headquarters.
The Compliance Challenge: Clinical Data Under China’s DSL
MedBridge Health’s China subsidiary had been conducting Phase III clinical trials for a new cardiovascular therapy since 2022. Under the DSL, which took effect on September 1, 2021, and the accompanying Data Security Assessment Measures (September 1, 2022), all clinical trial data—including patient health information, biomarker results, and treatment outcomes—falls under “important data” (重要数据, zhòngyào shùjù) when it involves Chinese citizens. This classification triggers mandatory security assessments for any cross-border transfer.
The US parent company required access to raw clinical data for FDA submission preparation, creating a direct conflict with DSL requirements. MedBridge’s initial approach—using encrypted email and a US-hosted cloud platform—had no legal basis under Articles 31-36 of the DSL, which mandate a two-step process: first, a data security self-assessment, and second, approval from the Cyberspace Administration of China (CAC) via a provincial-level data security assessment.
The specific number at stake was 120,000 patient records, each containing between 25 and 40 data fields. MedBridge faced a potential liability of 50 million yuan (approximately $7 million) under Article 45 of the DSL, which imposes fines of up to 5% of previous-year revenue for serious violations involving important data. With MedBridge’s China subsidiary generating $120 million in 2024 revenue, the maximum fine could have reached $6 million.
Data Mapping and Classification Under DSL
The first phase of MedBridge’s compliance project—lasting five months—involved a complete data mapping of all clinical data flows between its China subsidiary in Shanghai and its US headquarters in Boston. Under the DSL, data mapping must identify: the type of data, the volume of records, the sensitivity level, the storage location, and all third-party data processors.
The table below shows MedBridge’s final data classification framework, which was reviewed and accepted by the Shanghai Data Security Administration:
| Data Category | Examples | DSL Classification | Volume (Records) | Transfer Allowed? |
|---|---|---|---|---|
| Patient identifiers | Name, ID number, phone | Important data | 120,000 | No — must be de-identified |
| Clinical outcomes | Lab results, imaging, vitals | Important data | 120,000 | Yes — with CAC approval |
| Biomarker sequences | Genomic, proteomic data | Important data | 12,000 | Yes — with enhanced consent |
| Treatment protocol | Drug dosage, timing | General data | 300 | Yes — no restriction |
| Audit logs | Access records, timestamps | General data | 50,000 | Yes — with logging |
This classification revealed that 120,000 out of 120,000 patient records contained important data, meaning 100% of the dataset required CAC-level approval. The biomarker data—12,000 records—required additional informed consent under China’s Biosecurity Law (生物安全法, shēngwù ānquán fǎ), effective April 15, 2021. MedBridge had not obtained this consent, creating a secondary compliance gap.
Pitfall 1: MedBridge initially assumed that de-identification alone would exempt its data from DSL restrictions. However, Article 32 of the DSL requires that even de-identified important data undergo a security assessment if transferred abroad. Cost: Delayed the project by 4 months and added 1.8 million yuan in legal and technical consulting fees. Fix: Engage a certified Chinese data security assessor (测评机构, cèpíng jīgòu) before any transfer planning.
The Secure Transfer Solution: Technical + Legal Integration
MedBridge’s final solution combined three layers of technical and legal controls, designed during a six-month implementation phase:
Layer 1 — Data Minimization and De-identification in China. All 120,000 records were first processed in a secure on-premises server in Shanghai. Direct identifiers (name, ID number, phone) were replaced with pseudonymous tokens using a SHA-256 hashing algorithm. This reduced the data volume for transfer from 120,000 records to 120,000 de-identified records—but importantly, the tokens were stored on a separate server in China, with the lookup table kept offline. Under DSL Article 38, this separation ensures that the US parent cannot re-identify patients without a separate authorization.
Layer 2 — Localized Data Processing with a WFOE. MedBridge established a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) in Shanghai in 2023 specifically for clinical data operations. The WFOE contracted with a Chinese cloud provider—Alibaba Cloud—to host the de-identified data on a server located in Beijing. Under the Cybersecurity Law (网络安全法, wǎngluò ānquán fǎ), effective June 1, 2017, and the DSL, all important data must remain within China unless an approved transfer mechanism exists. Alibaba Cloud’s data localization certification provided the first layer of legal compliance.
Layer 3 — CAC Security Assessment and Cross-Border Data Transfer Agreement. MedBridge submitted a 247-page application to the Shanghai branch of the CAC, including: data classification results, a data security self-assessment report, a signed cross-border data transfer agreement between the China WFOE and the US parent, and evidence of patient consent for cross-border use. The CAC approved the application after a 94-day review—faster than the average 120-day review period for healthcare data. The approval allowed the transfer of up to 120,000 records per year for 24 months, with mandatory annual re-assessment.
Pitfall 2: The US parent company attempted to retain full administrative access to the Alibaba Cloud server, which violated Article 36 of the DSL—foreign entities cannot directly control systems hosting Chinese important data. Cost: CAC application was paused for 3 weeks, and MedBridge incurred 700,000 yuan in contract renegotiation fees to transfer admin control to the China WFOE. Fix: Ensure that the China subsidiary—not the US parent—holds the cloud service contract and admin credentials.
Pitfall 3: MedBridge failed to include Chinese-language patient consent forms in the initial CAC application, which is a requirement under Article 12 of the Personal Information Protection Law (个人信息保护法, PIPL, gèrén xìnxī bǎohù fǎ), effective November 1, 2021. Cost: The CAC required a re-submission, delaying the approval by 45 days and costing 350,000 yuan in legal rework. Fix: Prepare all consent documents in both English and Chinese, with notarized translations, and include them in the first submission.
Key Outcomes and Lessons for Cross-Border Clinical Data
MedBridge’s total compliance project cost was 12.5 million yuan over 14 months, broken down as: legal fees (4.2 million yuan), technical implementation (5.1 million yuan), CAC application support (1.8 million yuan), and contingency (1.4 million yuan). The alternative—proceeding without compliance—would have carried a maximum fine of 50 million yuan, plus potential criminal liability for executives under Article 47 of the DSL (up to 7 years imprisonment for serious violations involving important data).
The project delivered three measurable outcomes: full CAC approval for 24 months, a reusable compliance framework for future clinical data transfers, and a verified data security management system (DSMS) aligned with China’s GB/T 41479-2022 standard for data security. MedBridge has since used this framework to approve two additional cross-border transfers for other clinical trials.
Decision Framework for Other Healthcare Providers:
If your clinical data volume exceeds 100,000 records, choose a full CAC security assessment pathway with a dedicated WFOE. If your data volume is under 10,000 records and contains no biomarker or genomic data, choose a streamlined standard contractual clauses (SCC) approach under the PIPL, which avoids the CAC’s direct approval process but still requires a self-assessment. If your data includes genomic sequences, choose the enhanced pathway with additional consent under the Biosecurity Law, as MedBridge’s 12,000 biomarker records required.
Compliance Timeline Comparison
The table below compares MedBridge’s actual timeline with the typical timeline for similar projects in China’s healthcare sector (based on public CAC data and industry reports):
| Phase | MedBridge Actual Time | Industry Average Time | Key Variance Factor |
|---|---|---|---|
| Data mapping and classification | 5 months | 6 months | Used automated scanning tools (faster) |
| Technical implementation (de-identification, cloud setup) | 6 months | 8 months | Pre-existing WFOE and Alibaba Cloud relationship (faster) |
| CAC application preparation and submission | 3 months | 4 months | Hired a former CAC assessor as consultant (faster) |
| CAC review and approval | 3.1 months (94 days) | 4 months (120 days) | Complete application, no major errors (faster) |
| Total | 14 months | 22 months | — |
The 8-month time savings for MedBridge compared to the industry average came from three factors: a pre-existing WFOE structure, automated data mapping tools, and a former CAC assessor on the consulting team. This suggests that early structural preparation—especially establishing a WFOE and using Chinese cloud providers—can dramatically reduce compliance timelines even for complex clinical data transfers.
NEXT STEPS
- Assess your current clinical data flows – Map all data types, volumes, and transfer routes between your US and China operations. Use the table above as a reference template. Start with a free self-assessment template at: www.china-gateway360.com/tools/clinical-data-dsl-assessment
- Establish a China legal entity if one does not exist – A WFOE or 外商投资企业 (wàishāng tóuzī qǐyè) is the minimum requirement for hosting important data. Read our setup guide at: www.china-gateway360.com/guides/wfoe-setup-china-2025
- Begin the CAC security assessment process – Prepare your data classification report, self-assessment, and bilingual consent forms. Use our checklist at: www.china-gateway360.com/checklists/cac-data-security-assessment-healthcare
— China Gateway 360 —
Remote China market entry support, built around execution.
